Revamped Lundbeck Ups Outlook Amid Strong Brintellix and Rexulti Sales
Executive Summary
The rebounding Danish CNS specialist raised its 2016 revenue and profit forecasts as it continued to benefit from an ongoing structuring and buoyant sales in the US market, notably for its drugs Brintellix and Rexulti.